Novel Chemical "Dye" Improves Liver Cancer Imaging
A novel nondiamond-based contrast agent has been developed by a team of scientists from the National University of Singapore. The chemical "dye" can be used to enhance the visibility of internal body structures in MRI and can improve the visualisation of liver cancer tumours. This in turn can facilitate earlier detection and improved treatment strategies.
See Also: Simultaneous PET/MR Imaging - Key Benefits
MRI is commonly used for cancer diagnosis as well as to track patient progress after treatment. There are generally two modes of MRI imaging - T1-weighted and T2 weighted imaging. Contrast agents are often used to improve imaging quality but each imaging mode requires a specific class of contrast agents which cannot be used together. This can make liver cancer diagnosis more challenging, especially since T2-weighted imaging is not completely reliable and both T1 and T2-weighted imaging can be confounded by tumour vascularity.
This new contrast agent developed by the NUS research team led by Assistant Professor Edward Chow, Principal Investigator from the Cancer Science Institute of Singapore at NUS and Department of Pharmacology at NUS Yong Loo Lin of Medicine could provide clearer and more accurate images of tumours in both T1 and T2-weighted MRI scans and with lower dosages of contrast agents.
The dye was developed using nondiamonds in combination with a manganese base. Nondiamonds are carbon-based particles around two to eight nanometres in diameter and have properties that attract water molecules. This promotes proton exchange between water molecules and paramagnetic ions thus enhancing T1 and T2 relaxation and providing higher quality images.
The research team found that with this novel compound, liver tumours that could not be visualised without contrast agents became easily visible at low dosages.
“Our experiments suggest that our dual-mode contrast agent holds great promise in improving imaging for liver cancer. We are hopeful that this advancement in nanomedicine will lead to safer and more accurate diagnosis of liver cancer. Moving forward, we plan to conduct further pre-clinical safety studies for our contrast agents, with the end goal being clinical implementation. We are also looking into using our contrast agents to improve imaging for glioma and ovarian cancer,” said Asst Prof Chow.
Source: National University of Singapore
Image Credit: National University of Singapore
Published on : Sat, 6 May 2017
Introducing a new chapter in ultrasound visualization technology. X-Porte was developed from the ground up to incorporate a breakthrough, proprietary beam-forming technology: XDI (Extreme Definition Imaging). This signal analysis algorithm shapes...
THE VEVO MD IS THE WORLD’S FIRST ULTRA HIGH FREQUENCY ULTRASOUND SYSTEM DESIGNED FOR CLINICAL USE WITH FREQUENCIES UP TO 70 MHz. This groundbreaking technology opens up new possibilities for medical imaging that have never been seen before. Whether...
The SonoSite EDGE II is a high-resolution, all-digital, 9.0-pound (4.1 kg) ultrasound system with a 12.1in. LED full-bleed glass display. The Edge II boosts improvements in cardiac and abdominal image quality through DirectClear Technology and a new...
Shown to improve comfort in 93% of patients who reported moderate to severe discomfort with standard compression technology2 Curved, unique design mirrors the shape of a woman’s breast to reduce pinching and apply uniform compression over the entire...
Powered by the most revolutionary ZONE Sonography® Technology, Resona 7’s new ZST+ platform brings the ultrasound image quality to a higher level by zone acquisition and channel data processing. Resona 7 also provides clinical research with the revolutionary...